Half of US commercial health plans add coverage limits for gene and cell therapies beyond what they're approved for, ...
Zacks Investment Research on MSN
Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?
Krystal Biotech, Inc.’s KRYS lead drug Vyjuvek is a non-invasive, topical, redosable gene therapy approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa ...
Post-CAR T infection prophylaxis should follow European Hematology Association/European Society for Blood and Marrow ...
Syntara Limited ( OTCPK:PMXSF) Shareholder/Analyst Call September 29, 2025 9:00 PM EDT ...
It is well established that gut microbiome composition plays a pivotal role in human health—yet the precise connections are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback